ALYREF and neoplasm: To determine whether rhAPE1/Ref-1 or ASA affects TNBC tumor-specific biomarkers, changes in CEA, CA27-29, and CA15-3 plasma levels in the normal, TNBC control, rhAPE1/Ref-1-treated, ASA-treated, rhAPE1/Ref-1+ ASA-treated, and PTX-treated groups were examined.